Cord Blood News Volume 4.02 | Jan 19 2012

    0
    95

    Cord Blood News 4.02, January 19, 2012

         In this issue: Publications | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Cord Blood News on Twitter

    TOP STORY
    Human Umbilical Cord Mesenchymal Stromal Cells Mitigate Chemotherapy-Associated Tissue Injury in a Pre-Clinical Mouse Model
    Researchers evaluated the prophylactic and therapeutic action of human umbilical cord mesenchymal stromal cells on the chemotherapy agent adriamycin-induced side-effects in two different tumor models. [Cytotherapy] Abstract

    Improve Quality Control and Regulatory Compliance. Watch the video to see how StemLab can help.

    PUBLICATIONS (Ranked by Impact Factor of the Journal)

    Engraftment of Human HSC in Non-Irradiated Newborn NOD-scidIL2rγnull Mice Is Enhanced by Transgenic Expression of Membrane-Bound Human Stem Cell Factor
    Researchers hypothesized that transgenic expression of human membrane-bound stem cell factor would increase levels of human hematopoietic stem cell (HSC) engraftment in non-irradiated NOD-scidIL2rγnull (NSG) mice and eliminate complications associated with irradiation. Surprisingly, detectable levels of human CD45+ cell chimerism were observed following transplantation of cord blood-derived human HSC into non-irradiated adult as well as newborn NSG mice. [Blood] Abstract

    Unrelated Cord Blood Transplantation for Newly Diagnosed Patients with Severe Acquired Aplastic Anemia Using a Reduced-Intensity Conditioning: High Graft Rejection, but Good Survival
    Investigators report a single-center experience in treating 18 consecutive patients with severe aplastic anemia who received unrelated cord blood transplantation. [Bone Marrow Transplant] Abstract

    The Use of Back-Up Units to Enhance the Safety of Unrelated Donor Cord Blood Transplantation
    Researchers demonstrate that back-up units are emergently required in a significant minority of patients supporting the incorporation of at least one back-up unit in cord blood (CB) selection algorithms to enhance CB transplantation. [Biol Blood Marrow Transplant] Abstract

    Production of Large Numbers of Plasmacytoid Dendritic Cells with Functional Activities from CD34+ Hematopoietic Progenitor Cells: Use of Interleukin-3
    As plasmacytoid dendritic cells (pDC) represent a rare cell type in the peripheral blood, the goal of this study was to develop a new method to efficiently generate large numbers of cells from a limited number of CD34+ cord blood progenitors in order to provide a tool to resolve important questions about how pDC mediate tolerance, autoimmunity and cancer. [Exp Hematol] Abstract

    Polyunsaturated Fatty Acids Confer Cryoresistance on Megakaryocytes Generated from Cord Blood and Also Enhance Megakaryocyte Production from Cryopreserved Cord Blood Cells
    In this study, cryopreservation of ex vivo-expanded megakaryocytes (MK) as well as MK generation from cryopreserved umbilical cord blood samples was investigated. [Cytotherapy] Abstract

    Ectopic Expression of the Histone Methyltransferase Ezh2 in Hematopoietic Stem Cells Causes Myeloproliferative Disease
    Here researchers show that induced Ezh2 hematopoietic expression increases the number and proliferation of repopulating hematopoietic stem cells. [Nat Commun] Abstract

    Tech Bulletin: Expansion Of Hematopoietic Stem And Progenitor Cells

    INDUSTRY NEWS

    CIRM Allocates $40 Million to Support Stem Cell Genomics, Speeding Development of Therapies for Patients
    California stem cell scientists will have a new resource for advancing therapies with a $40 million initiative approved today by the governing board of the California Institute for Regenerative Medicine (CIRM). [California Institute for Regenerative Medicine] Press Release

    Making Safer Chemicals: New NIH Grant Helps Researchers Study How Chemicals in Drugs and Around Us Impact Stem Cells
    Bioengineers at Rensselaer Polytechnic Institute and the University of California, Berkeley, have been awarded a more than $2 million grant from the National Institutes of Health (NIH) to study how chemicals in drugs and our environment impact our stem cells. [Rensselaer Polytechnic Institute] Press Release

    SpineSmith Adds Talented Scientist to Research and Development Team
    SpineSmith is pleased to announce the addition of Dr. Matthew Murphy to its team of PhDs. [PR Newswire] Press Release

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS
    NEW Drug Discovery World Asia
    March 19-22, 2012
    Singapore, Singapore

    Visit our events page to see a complete list of events in the cord blood community.

    JOB OPPORTUNITIES

    Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

    Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

    Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

    Business Analyst – Product Management (STEMSOFT Software)

    Laboratory Supervisor – Cellular Therapy (NewYork-Presbyterian Hospital)

    Cell Therapy Technician (Kelly Scientific Resources)


    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

    Visit here to post your career opportunities.

    Have we missed an important article or publication in Cord Blood News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Cord Blood News: Archives | Events | Contact Us